Restalyst

Imagine a world where early cancer detection can save countless lives. Driven by this mission since its inception in 2007, Restalyst is dedicated to advancing the frontier of biomedical research and development.

Fueled by a commitment to innovation, we have leveraged proprietary protein biomarkers to commercialise three groundbreaking diagnostic tests tailored for the early detection of gastric, liver, and nose cancers—GC-REAAD™ ITIH3 ELISA, HCC-REAAD™ ERBB3 ELISA, and NPC-REAAD™ EBV EA-IgA ELISA respectively. These tests have yielded remarkable results, with over 1.6 million diagnostic tests performed regionally, potentially leading to earlier diagnoses and improved treatment outcomes for patients.

Our dedication extends beyond research and development. As a fully integrated organisation, our state-of-the-art facilities with EN ISO13485 certification ensures the highest standards of quality and precision in every diagnostic solution. This meticulous approach translates directly to patient benefits, enabling earlier diagnoses and improved treatment outcomes.

While rooted in Singapore, Restalyst’s impact knows no bounds. With a strong market presence in Southeast Asia, we actively seek partnerships to bring our innovative solutions to healthcare providers and patients worldwide. Through a global network, we strive to be a leading in-vitro diagnostics manufacturer, offering affordable and accessible diagnostic tools in the fight against cancer.